Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
Portfolio Pulse from
Eli Lilly reported mixed fourth-quarter results with strong demand for its weight loss and diabetes drugs, but faced lower realized prices. U.S. demand for incretin drugs like Zepbound and Mounjaro has outpaced supply.
February 06, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly's Q4 results show strong demand for its weight loss and diabetes drugs, but lower realized prices. U.S. demand for incretin drugs like Zepbound and Mounjaro has outpaced supply.
Eli Lilly's strong demand for its drugs is a positive indicator, but the impact of lower realized prices balances the outlook. The supply-demand imbalance in the U.S. could affect future revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100